ReviewPharmaceutics2021
Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Co-Amorphous Ursolic Acid-Quercetin Complex Improves Solubility and In Vivo Expectorant-Antitussive Activity.Plants (Basel, Switzerland) · 2026Article
- Co-amorphization for solubility and dissolution rate improvement: the case of low-crystallization-tendency drugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- From Chemistry to Clinic: Amorphous Solid-State Modification Strategies for Oral Azole Antifungals.ACS omega · 2026Review
- Capric Acid-Based Therapeutic Deep Eutectic Systems: A Focused Review Within the Framework of Deep Eutectic Solvents.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Comprehensive Review of Mesoporous Carbon and Mesoporous Silica in Poorly Soluble Drug Delivery: Insights into Drug Loading, Dissolution, Stability, and Pharmacological Performance.International journal of nanomedicine · 2026Review
- Recent Advances in Glimepiride Solubility Improvement: A Focus on Formulation Technologies - A Narrative Review.International journal of nanomedicine · 2026Review
- Two Drug-Drug Co-Amorphous Systems of Curcumin and Berberine Hydrochloride/Palmatine Hydrochloride with Improved Physicochemical Properties and Multifunctional Activities.Pharmaceutics · 2025Article
- Development of an inhalable dry powder formulation for inhibition of SARS-CoV-2.International journal of pharmaceutics: X · 2025Article
- Co-amorphous Approach for Enhancing Rilpivirine Oral Bioavailability using CYP3A4 Inhibitor as a Co-former.AAPS PharmSciTech · 2025Article
- Development of Co-Amorphous Systems for Inhalation Therapy-Part 2: In Silico Guided Co-Amorphous Rifampicin-Moxifloxacin and -Ethambutol Formulations.Pharmaceutics · 2025Article
- Dissolution Amelioration by Small Amounts of HPMC in the Difficult-to-solve Drug Combination Baicalein-imperatorin Co-Amorphous System: Dispersion and Crystallization Inhibition.AAPS PharmSciTech · 2025Article
- The Development and Characterization of Layered Pellets Containing a Combination of Amorphized Amlodipine Besylate and Hydrochlorothiazide Using a High-Shear Granulator.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Development of Co-Amorphous Systems for Inhalation Therapy-Part 1: From Model Prediction to Clinical Success.Pharmaceutics · 2025Article
- Breaking barriers: enhancing solubility and dissolution of efonidipine using co-amorphous formulations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Preparation and Characterization of Vitamin D3-Based Binary Amorphous Systems.Foods (Basel, Switzerland) · 2025Article
- Long-Term Stabilized and Highly Soluble Bezafibrate-Gliclazide Co-Amorphous Binary System.AAPS PharmSciTech · 2025Article
- Formulation Strategies for Ezetimibe and Its Combinations: Advancing Biopharmaceutical and Therapeutic Potential.Drug design, development and therapy · 2025Review
- Development of a Novel Co-Amorphous Curcumin and L-Arginine (1:2): Structural Characterization, Biological Activity and Pharmacokinetics.Pharmaceutics · 2024Article
- Selective Laser Sintering 3D Printing of Carvedilol Tablets: Enhancing Dissolution Through Amorphization.Pharmaceutics · 2024Article
- The Effects of Novel Co-Amorphous Naringenin and Fisetin Compounds on a Diet-Induced Obesity Murine Model.Nutrients · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Co-amorphous drug delivery systems (CAMS) are characterized by the combination of two or more (initially crystalline) low molecular weight components that form a homogeneous single-phase amorphous system. Over the past decades, CAMS have been widely investigated as a promising approach to address the challenge of low water solubility of many active pharmaceutical ingredients. Most of the studies on CAMS were performed on a case-by-case basis, and only a few systematic studies are available. A quantitative analysis of the literature on CAMS under certain aspects highlights not only which aspects have been of great interest, but also which future developments are necessary to expand this research field. This review provides a comprehensive updated overview on the current published work on CAMS using a quantitative approach, focusing on three critical quality attributes of CAMS, i.e., co-formability, physical stability, and dissolution performance. Specifically, co-formability, molar ratio of drug and co-former, preparation methods, physical stability, and in vitro and in vivo performance were covered. For each aspect, a quantitative assessment on the current status was performed, allowing both recent advances and remaining research gaps to be identified. Furthermore, novel research aspects such as the design of ternary CAMS are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.